# Retrospective Study on the Safety and Therapeutic/Improvement Effects of Intravenous Administration of SHED-CM for ALS (SHED-CAH2023)

> **NCT06608719** · — · COMPLETED · sponsor: **Hitonowa Medical** · enrollment: 24 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **BIOLOGICAL:** The study drug is SHED-CM manufactured by U-Factor

## Key facts

- **NCT ID:** NCT06608719
- **Lead sponsor:** Hitonowa Medical
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-25
- **Primary completion:** 2024-07-01
- **Final completion:** 2024-07-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06608719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06608719, "Retrospective Study on the Safety and Therapeutic/Improvement Effects of Intravenous Administration of SHED-CM for ALS (SHED-CAH2023)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06608719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*